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INTRODUCTION
Previous investigations have indicated that sev-
eral kinds of trypsin-like enzymes are biosynthesized
or released in the airway (1-6). Mast cells releases
trypsin-like protease (tryptase) into extracellular
spaces of the airway (1). Human mast cell tryptase
(MCT) has an apparent molecular weight of 144
kDa and consists of two subunits of 37(or 30.9)
kDa and two subunits of 35(or 31.6) kDa (7-8). Kido
et al. have shown in rats that Clara cells located only
in the wall of the distal airway secrete a trypsin-like
protease (tryptase Clara) with an apparent molecu-
lar weight of 180 kDa (2). Kawano et al. (4) and
ORIGINAL
Effect of human airway trypsin-like protease on intracellular
free Ca2+ concentration in human bronchial epithelial
cells
Mari Miki§,＊, Yoichi Nakamura＊, Akira Takahashi†, Yutaka Nakaya†,
Hiroshi Eguchi‡, Tsukio Masegi‡, Kazuo Yoneda§, Susumu Yasuoka†,
Saburo Sone§
§Department of Internal Medicine and Molecular Therapeutics, The University of Tokushima
School of Medicine, Tokushima, Japan ; ＊Department of Clinical Research, Kochi National Hospital,
Kochi, Japan ; †Department of Nutrition, The University of Tokushima School of Medicine,
Tokushima, Japan ; and ‡Teijin Institute for Biomedical Research, Hino, Tokyo, Japan
Abstract : It has been shown that human airway trypsin-like protease (HAT) is localized
in human bronchial epithelial cells (HBEC), and trypsin activates protease-activated receptor-2
(PAR-2). Activation of PAR-2 activates G-protein followed by an increase of intracellular
free Ca2+, [Ca2+]in. This study was undertaken to clarify whether HAT can activate PAR-2
in HBEC or not. RT-PCR showed that HAT mRNA is expressed in HBEC, and PAR-2 mRNA
is the most strongly expressed of the known PARs in HBEC. Both PAR-2 agonist peptide
(PAR-2 AP) and HAT increased [Ca2+]in in HBEC in a biphasic fashion ;a prompt, sharp
increase (peak I) and a sustained low plateau (peak II). PAR-2 AP over 100-200 µM and
HAT over 200-300 mU/ml (0.08-0.12 µM) induced both peak I and II, and PAR-2 AP below
100 µM and HAT below 200 mU/ml induced only peak II. Both PAR-2 AP-induced and
HAT-induced peak I were induced by Ca2+ mobilization from intracellular stores, because
they appeared even in Ca2+-free medium. Both PAR-2 AP-induced and HAT-induced peak
II were induced by an influx of extracellular Ca2+, because they were abolished in Ca2+-free
medium. The Ca2+ response to HAT was desensitized by exposure of HBEC to PAR-2 AP.
These results indicate that HBEC have a functional PAR-2, and HAT regulates cellular
functions of HBEC via activation of PAR-2. J. Med. Invest. 50 : 95-107, 2003
Keywords : human airway trypsin-like protease (HAT), human bronchial epithelial cells (HBEC), protease-activated
receptor-2(PAR-2), intracellular calcium,
Received for publication December 19, 2002 ; accepted Janu-
ary 8, 2003.
Address correspondence and reprint requests to Saburo Sone,
M.D., Department of Internal Medicine and Molecular Therapeutics,
The University of Tokushima School of Medicine, Kuramoto-cho,
Tokushima 770-8503, Japan and Fax : +81-88-633-2134.
The Journal of Medical Investigation Vol. 50 2003
９５
Cocks et al. (5) have reported that a positive reac-
tion to antibody against human trypsin (organ) is
detectable in normal human airway epithelial cells
and gland cells by immunohistochemistry.
Yasuoka et al. isolated a novel, monomeric trypsin-like
protease with a molecular weight of 27 kD from
the mucoid sputum of patients with chronic airway
diseases and named this novel enzyme human air-
way trypsin-like protease (HAT) (3). Yamaoka et al.
cloned the cDNA of HAT and indicated that HAT
has a precursor form of 47 kDa, because the de-
duced polypeptide consisted of a 232-residue cata-
lytic region and a 186-residue noncatalytic region
with a hydrophobic putative transmembrane do-
main near the NH2-terminus. Takahashi et al. have
immunohistochemically examined the localization
of HAT in the airways and have shown that a posi-
tive reaction to a monoclonal antibody to HAT is
localized at ciliated bronchial epithelial cells, but
not detectable at the submucosal layer of the air-
ways (10). These results strongly suggest that pre-
cursor HAT may be synthesized in the airway epi-
thelial cells and converted into the active HAT by
limited proteolysis.
Previous investigations have suggested that
trypsin-like proteases might be involved in the
pathogenesis of inflammation, infection and fibrotic
processes in the airway and lung. For example, MCT
has been reported to play some pathophysiological
roles in airway diseases like bronchial asthma (11-
12) and pulmonary fibrosis (13-14). Kido et al. showed
that tryptase Clara activates the infectivity of influ-
enza A virus (2). However, the physiological and
pathophysiological roles of HAT are unknown.
Recently, it has been clarified that certain serine
proteases such as thrombin and trypsin, which
have been considered to participate principally in
the degradation of extracellular proteins, are also
signaling molecules that regulate multiple cellular
functions by activating specific receptors (5-6, 15-
20). The receptors, protease-activated receptors
(PARs), are a family of G-protein-coupled receptors
(21). These receptors are activated by the proteolytic
cleavage of a receptor-bound, NH2-terminal tethered
ligand domain, which is then able to bind to the
receptor and initiate signaling (20). Four PARs
(PAR1-4) have been characterized (15-19). Tryp-
sin (16 -17) and MCT (22-23) activate PAR-2. Re-
cent evidence indicates that PAR-2 is present in
epithelial cells (5-6, 18, 20), endothelial cells (24),
smooth muscle cells (5, 25), fibroblasts (23) and
neutrophils (26), and may participate in the regu-
lation of functions of enterocytes (27), keratinocytes
(28), neutrophils (26) and bronchial epithelial cells
(5-6, 29), and can play some role in inflammatory
conditions (5-6, 12, 24, 26, 28).
As described above, PARs are localized on cell
surfaces and HAT, a trypsin-like protease, is also
thought to be localized on cell surfaces of airway
epithelial cells. Therefore, we thought that HAT
regulates the cellular functions of airway epithelial
cells via the activation of PARs in an autocrine or
paracrine manner. It has been established that the
activation of PARs activates the G-proteins followed
by an increase of intracellular Ca2+ (21). In this work,
we studied the effect of HAT on the intracellular
Ca2+ concentration in primary human bronchial
epithelial cells, to determine whether HAT regu-
lates the cellular functions of airway epithelial
cells via the activation of PARs.
MATERIALS AND METHODS
Materials
Benzamidine-Sepharose 6B was purchased from
Pharmacia Fine Chemicals (Uppsala, Sweden), and
SP-Toyopearl 650M (a cation-exchange gel) was
from TOSOH (Tokyo, Japan). M-PerTM (a mamma-
lian protein extraction reagent) was purchased from
Pierce (Illinois, USA), and Triton X-100, PEG-6000,
bovine serum albumin (BSA) and U73122, an inhibitor
of phospholipase C, were from Sigma (St Louis,
MO, USA). Methylcoumarinamide (MCA)-substrates
for the assay of trypsin-like activity were obtained
from Peptide Institute (Osaka, Japan). Heparin so-
dium salt from porcine intestinal mucosa was ob-
tained from Calbiochem (La Jolla, CA, USA). Gra-
dient gels (Multigel 10/20) and a silver-staining kit
were obtained from Daiichi Pure Chemicals (Tokyo,
Japan), and prestained low range protein standards
were obtained from Bio-Rad Laboratories (Hercules,
CA, USA).
Fetal bovine serum (FBS) was obtained from
Gibco (Grand Island, NY, USA). A type II collagen
(Vitrogen 100) was obtained from Collagen Co. (CA,
USA). Tissue culture plates were purchased from
Becton Dickinson Labware (Franklin Lakes, NJ).
1-(2-(5’-carboxyoxazol-2’-yl)-6-aminobenzofuran-5-
oxy)-2(2’amino-5-methylphenoxy) ethane-N, N, N’,
N’-tetraacetic acid, pentaacetoxy methylester (fura-2/
AM) was obtained from Molecular Probes (Eugene,
OR, USA). The human PAR-2 agonist peptide, con-
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sisting of the amino acid sequence (SLIGKV-NH2)
was obtained from BACHEM (Bubendorf, Switzer-
land). The primers for RT-PCR of mRNA of HAT
and PAR1-4 were synthesized in our laboratory.
Bradykinin was obtained from Wako Pure Chemi-
cals (Osaka, Japan).
Human Bronchial Epithelial Cells (HBEC)
Primary human bronchial epithelial cells (HBEC)
were collected by brushing the bronchial mucosa
of healthy volunteers under bronchoscopy with lo-
cal anesthesia. Before the study, written informed
consent was obtained from all volunteers after a full
explanation of the procedures involved. The cells obtained
by brushing were collected in 50 ml polypropylene
tubes containing 20 ml RPMI-1640 with 10% FBS,
and then washed with RPMI-1640 by centrifugation
at 400 g at 4℃ for 10 min. The rinsed pellets of cells
were resuspended in LHC-9 (30)/RPMI-1640 medium
in which a mixture of an equal volume of LHC-Basal
medium and RPMI-1640 medium was supplemented
with bovine pituitary extract (BPE), hydrocortisone,
human recombinant epidermal growth factor (rEGF),
epinephrine, transferrin, insulin, retinoic acid,
triiodothyronine, ethanolamine, o-phophoethanolamine
and gentamycin. The cells were plated in 24-well
culture plates coated with Vitrogen, and incubated
at 37℃ in a humidified 5% CO2 in air atmosphere.
The medium was changed every other day until
the cells had grown to 90% confluence. Then, the
cells were passaged with 0.125% trypsin/0.1% EDTA
in PBS and seeded for use in the next study. Ex-
periments were performed with cell passages 1
(P1) and P2.
Other respiratory cells
Normal human small airway epithelial cells (SAEC)
and normal human lung fibroblasts (NHLF) were obtained
from BioWhittaker (Walkersville, MD, USA). BEAS-2B,
a transformed human bronchial epithelial cell line,
and A549, a human alveolar cell line, were obtained
from American Type Culture Collection (Rockville,
MD, USA). Human alveolar macrophages (HAM)
were collected by segmental bronchoalveolar lavage
from normal volunteers as previously reported (3１).
SAEC and BEAS-2B were cultured in LHC-9/RPMI-1640
as described for the HBEC, and HAM, NHLF and
A549 were cultured in Dulbecco’s modified Eagle’s
medium (DMEM)/10% FBS.
Preparation of recombinant HAT
Recombinant HAT (rHAT) was expressed in in-
sect cells infected with baculovirus carrying HAT
cDNA as previously reported (9). The rHAT was
purified by a modification of the method used to
purify the native HAT (3).
Briefly, a cell pellet from about 400 ml of the cul-
ture broth of insect cells was suspended in 100 ml
of M-PerTM, and this mixture was stirred at room
temperature for 2 hrs, then centrifuged at 10,000
rpm for 20 min at room temperature. The pellet
(pellet I) was preserved for a second purification.
The supernatant was dialyzed against 2.5 liters of
50 mM Na acetate buffer (pH 4.0)/0.01%PEG6000
for 2 hrs, and centrifuged at 10,000 rpm for 20 min.
The pellet (pellet II) was also preserved for a second
purification, and the supernatant was dialyzed against
50 mM Tris-HCl buffer (pH 8.0)/0.5 M NaCl/0.01%
PEG6000 for 4 hrs and the latter dialysis buffer was
changed after 2 hrs. Each half of the supernatant
was applied to a column (bed volume 5 ml) of
Benzamidine-Sepharose 6B equilibrated with the
latter dialysis buffer. After the column was succes-
sively washed with 50 ml of the latter dialysis buff-
er, 25 ml of 10 mM Na phosphate buffer (pH 8.0),
rHAT adsorbed on the column was eluted with 10
mM HCl (pH2.0) in a 0.5-ml fraction. The active
fractions from each column were collected, and pH
of this fraction was adjusted to 6-7 by adding a 1/
19 volume of 200 mM Na phosphate buffer.
The above-described pellets I and II were com-
bined, and suspended in 50 ml of M-PerTM/4% Triton
X-100/2% bile salts. The mixture was stirred at room
temperature for 2 hrs, and centrifuged at 10,000 rpm
for 2 min. The supernatant was dialyzed against 1
liter of 50 mM Na acetate buffer (pH 4.0)/0.01%
PEG6000 at room temperature for 4 hrs, the latter
dialysis buffer was changed after 2 hrs, and then
centrifuged at 10,000 rpm for 20 min at 4℃. The re-
sultant supernatant was applied to a column (bed
volume 4 ml) of SP-Toyopearl 650 M equilibrated with
the dialysis buffer. After the column was washed
with 40 ml of the equilibration buffer, rHAT was
eluted with 35 ml of 50 mM Tris-HCl buffer (pH
8.0)/0.5 M NaCl/0.01% PEG6000. After the eluate
was dialyzed against 1 liter of the elution buffer at
room temperature for 4 hrs with a buffer change
after 2 hrs, it was subjected to affinity chromatogra-
phy using Benzamidine-Sepharose 6B as described
above.
By the first and second purification, about 600µg
of rHAT was obtained. This purified material showed
a single band located in the position correspond-
ing to a molecular weight of about 27 kDa, under
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both reducing and non-reducing conditions on so-
dium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) carried out by the method of
Laemmli (32) (Fig. 1). The endotoxin level in the
purified rHAT was very low and routinely less than
15 pg/200 µg enzyme protein.
About 15 ml of the purified rHAT solution com-
posed of rHAT and Na phosphate buffer (pH 6-7)
was concentrated by ultrafiltration with an Amicon
membrane (YM-10), and the rHAT was washed with
10 ml of PBS 3 times by ultrafiltration. rHAT was
finally dissolved in 12 ml of PBS/BSA(100 µg/ml)
unless otherwise stated, and sterilized by filtration
through a Millipore PVDF membrane (0.22 µm, low
protein-binding).
Assay of Trypsin-like Activity
Assay of trypsin-like activity was measured by
the method of Yasuoka et al. (3). Briefly, the assay
mixture (1.5 ml) containing 50 mM Tris-HCl (pH
8.6), Boc-Phe-Ser-Arg-MCA at 100 µM, BSA at 100
µg/ml, and 100 µl of the test sample was incubated at
37℃ for 60 min, and the reaction was stopped by the addi-
tion of 1ml of 30% acetic acid. Then, the fluorescence
intensity of the released aminomethyl-coumarin (AMC)
was measured with fluorescence spectrophotometer
(F-3010 Hitachi Co, Japan) at 440 nm with excita-
tion at 380 nm. The amount of AMC released was
calculated from a standard curve. One unit of en-
zyme was defined as amount that produced 1 µmole
of AMC per min.
Reverse-transcription polymerase chain reaction
(RT-PCR) analysis of mRNA for PAR-1, 2, 3 and
4, and mRNA for HAT
1 RT-PCR for mRNA for PAR-1, 2, 3 and 4 in HBEC
Each of the respiratory cells were seeded into 6-
cm tissue culture dishes to 100% confluence. The
cells on each dish were lysed in 1 ml of ISOGEN,
a mixture of guanidium isothiocyanate and phenol
(Nippon Gene, Tokyo, Japan). From the lysed cells,
total cellular RNA was extracted with chloroform
and precipitated with isopropanol.
A mRNA-selective PCR Kit Ver.1.1 (Takara Shuzo
Co., Shiga, Japan) was used to amplify selectively
the mRNA-derived products. Total RNA(1 µg) was
reverse transcripted using this kit and some of the
reverse transcription products (cDNA) were used
as a template for PCR amplification. Briefly, the PCR
was performed for 25-30 cycles (denaturation at 85℃
for 45 sec, annealing at 58℃ for 45 sec and elongation
at 72℃ for 2 min). Sense primer and antisense
primer for PCR of each PAR-1, PAR-2, PAR-3 and
PAR-4 were synthesized according to the methods
of Kahn et al. (33), and their base sequences were
as
PAR-1. Sense primer : CAG TTT GGG TCT
GAA TTG TGT CG
Antisense primer : TGC ACG AGC TTA
TGC TGC TGA C
PAR-2. Sense primer : TGG ATG AGT TTT
GTG CAT CTG TCC
Antisense primer : CGT GAT GTT CAG
GGC AGG AAT G
PAR-3. Sense primer : TCC CCT TTT CTG
CCT TGG AAG
Antisense primer : AAA CTG TTG CCC
ACA CCA GTC CAC
PAR-4. Sense primer : AAC CTC TAT GGT
GCC TAC GTG C
Antisense primer : CCA AGC CCA GCT
AAT TTT TG
follows
The lengths of the expected PCR products were
as follows : PAR-1, 592 bp ; PAR-2 491 bp ; PAR-3 512 bp ;
PAR-4 542 bp. Products were electrophoresed on
1.5% agarose gels, stained with ethidium bromide
Fig. 1. Sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) of purified recombinant HAT (rHAT).
SDS-PAGE was carried out by the method of Laemmli (34).
About 0.3 µg of the purified rHAT was subjected to SDS-PAGE
on a multigel 10/20 under denaturing and reducing conditions
(lane 2) and non-reducing conditions (lane 3). The gels were
silver-stained using a kit obtained from Daiichi Pure Chemicals.
The gels were calibrated with prestained SDS-PAGE low range
standards (Bio-Rad Laboratories) (lane 1 : phosphorylase B (106
kDa), BSA (81 kDa), Ovalbumin (47.5 kDa), carbonic anhydrase
(35.3 kDa), soybean trypsin inhibitor (28.2 kDa), lysozyme
(20.8 kDa).
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solution and visualized by UV transillumination.
2 RT-PCR for mRNA for HAT in respiratory cells
Total RNA was extracted as described above from
each of the respiratory cells. RT-PCR was carried
out as described above. Sense and antisense primer
for this RT-PCR were synthesized, and the sequences
were as follows. Sense primer : 5’-CATTG TCGTC
GCAGG GGTAG-3’, Antisense primer : 5’-TCAGC
CTCAG TGCCT CCAAG-3’. The length of the ex-
pected PCR product was 519 bp.
Measurement of intracellular Ca2+ concentration
The concentration of intracellular free Ca2+ ([Ca2+]in)
was evaluated by microfluorometry with the fluo-
rescent dye, Fura-2/AM, at an excitation wavelength
of 340 nm and 380 nm, and at an emission wave-
length of 510 nm with a specially designed cham-
ber and an ARGUS-50/CA system (Hamamatsu
Photonics, Tokyo, Japan)(34). In each experiment,
the ratio of fluorescence at 340 nm to that 380 nm
was determined in 15-20 individual cells that were
selected with the system.
The HBEC in LHC-9/RPMI-1640 were seeded on
Vitrogen-coated coverslips (13 mm×13 mm) in a
6-well culture plate, and were grown to the 60-70%
confluence. After 5 days, the culture medium was
changed to RPMI-1640/0.01% BSA and the cells were
cultured for 1 day. On the day when the experi-
ment was carried out, HBEC on each coverslip were
loaded with 2 µM Fura-2/AM, unless otherwise stated,
in a Hepes buffer (10 mM Hepes, 145 mM NaCl, 5
mM KCl, 1 mM CaCl2, 1 mM MnCl2, 10 mM glu-
cose, pH 7.4) containing 0.01% BSA for 1 hr at 37
℃, and washed twice with the same buffer. The
coverslips were inserted into the chamber kept at
37℃ and were perfused with the same buffer con-
taining test samples for 30-60 min.
When the effect of rHAT on the HBEC was tested
in a Ca2+-free condition, a 10 mM Hepes buffer which
contained 1 mM EGTA instead of 1 mM CaCl2 was
used instead of the Hepes buffer.
The HAT or PAR-2 AP added to HBEC was pre-
pared in the Hepes buffer, warmed to 37℃ and then
perfused into the chamber. For desensitization ex-
periments, the solutions were perfused through
sequentially, without any separate washes between
treatments.
RESULTS
Expression of PAR-2 mRNA in HBEC
Total RNA obtained from the HBEC was sub-
jected to RT-PCR analysis for the detection of mRNA
of PAR-1, 2, 3 and 4. In the present experimental
conditions using PAR-1, 2, 3, 4 primer, only the
expression of PAR-2 mRNA was clearly detectable
in the HBEC (Fig. 2 A). This result strongly sug-
gested that primary HBEC contained more PAR-2
than other known PARs at their cell membranes,
because the expression of PAR-2 mRNA was the
most pronounced in the HBEC compared with
mRNA of other known PARs.
Expression of HAT mRNA in various respiratory
cells
The existence of HAT in the various respiratory
cells was investigated by analyzing the HAT mRNA
content with RT-PCR. HAT mRNA was clearly de-
tectable in only native bronchial epithelial cells,
namely HBEC and SAEC, while it was not detect-
able in BEAS-2B (a human bronchial cell line), hu-
man alveolar macrophages (HAM), an alveolar cell
line (A549) and NHLF, as shown in Fig. 2B. This
result is in accordance with the histochemical find-
ings of Takahashi et al. (10) that HAT is localized
at bronchial epithelial cells.
Stabilization of rHAT
This experiment was carried out using rHAT
dissolved in 0.15 M NaCl (pH 7.4) at a concentra-
tion of 40 µg/ml. The stability of rHAT was tested
at 37℃ at a concentration of 0.4 µg/ml in 50 mM
MES (pH 6.2), 50 mM Na phosphate buffer (pH 7.4)
and 50 mM Tris-HCl buffer (pH 8.6). When rHAT
was incubated in the absence of BSA at pH 7.4, its
activity declined to 33%, 10% and 5% of the original
activity after incubation for 1, 2 and 3 hrs, respec-
tively, and was completely lost after incubation for
24 hrs (Fig. 3). When rHAT was incubated in the
presence of 0.01% BSA at pH 7.4, its original activ-
ity remained even at 24 and 48 hrs after incubation
(Fig. 3). The stabilizing effect of BSA on rHAT was
almost the same at concentrations of 0.01%, 0.1%
and 1.0%, and also almost the same at any pH tested
(data not shown).
Schwarz et al. reported that even when mast cell
tryptase was incubated at 37℃ in 10 mM Tris-HCl
buffer (ph 7.4) containing 0.1% BSA and 0.15 M NaCl,
its activity rapidly declined to 50% and about 10%
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after incubation for 6-8 min, and 60 min, respec-
tively, and that heparin completely preserved its
activity during a 2-hr incubation at 37℃ at 50 µg/
ml (35). However, when rHAT was incubated at 50
mM MES (pH 6.2), 50 mM Na phosphate buffer
(pH 7.4) and 50 mM Tris-HCl buffer (pH 8.6) in
the presence of 0.1 to 100 µg/ml of heparin, its ac-
tivity declined rapidly as it was incubated at the ab-
sence of heparin (data not shown). Therefore, we
used 0.01% BSA as a stabilizer for rHAT in the fol-
lowing experiments.
Fig. 2. Analysis of the expression of protease-activated receptor (PAR)-1, 2, 3 and 4 mRNA in the HBEC and of the expression of
HAT mRNA in various respiratory cells by RT-PCR.
(A) The HBEC were proliferated in LHC9/RPMI-1640 to 100% confluence in a 60-mm dish. Total RNA was extracted from the
HBEC, and subjected to RT-PCR for PAR-1, 2, 3 and 4 as described in Materials and Methods. Briefly, total RNA (1 µg) was
subjected to RT reaction, and some of the products (cDNA) were amplified for 27 cycles with each specific primer. The products
were electrophoresed on 1.5% agarose gels. molecular markers ; 100 bp step ladder (Promega). (B) Various respiratory cells were
proliferated in each growth medium in a 60-mm dish. These cells except BEAS-2B and A549 were in passage 1 (P1) or P2 while
BEAS-2B were in P45. Total RNA was extracted from these cells, and subjected to RT-PCR for HAT mRNA as described in Materials
and Methods. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used as a control of HAT mRNA.
Abbreviations ; SAEC : normal human small airway epithelial cells, NHLF : normal human lung fibroblasts, A549 : a human pulmo-
nary epithelial cell line, BEAS-2B :a human bronchial epithelial cell line, HBEC : human bronchial epithelial cells, HAM : human
alveolar macrophages
Fig. 3. Stabilization of rHAT by BSA.
The rHAT dissolved in 2 ml of 50 mM
Na phosphate buffer (pH 7.4) at a con-
centration of 0.4 µg/ml was incubated
at 37℃ at the absence or presence of
0.01% of BSA. The trypsin-like activity
was measured at the time indicated in
the figure. The activity at each time
was expressed as % of the original ac-
tivity. Points show means of 3 experi-
ments.
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Effect of PAR-2 agonist peptide (PAR-2 AP,
SLIGKV-NH2) on intracellular Ca2+ concentration
([Ca2+]in) in HBEC
The result shown in Fig. 2A indicated that pri-
mary HBEC contained more PAR-2 than other known
PARs at their cell membranes. Previous investiga-
tors reported that when PARs of various kinds of
cells are activated by their agonists, serine proteases
or agonist peptides, the intracellular free Ca2+ con-
centration ([Ca2+]in) in the cells increased via a
G-protein-mediated mechanism. They utilized the
increase of [Ca2+]in as an indicator of the activation
of PARs by PAR agonists (12, 15-19, 26, 28, 29, 36).
Therefore, the increase of [Ca2+]in is thought to be
useful in estimating whether functional PAR-2 ex-
ists in HBEC stimulated with agonist serine protease
or PAR-2 agonist peptide.
When HBEC were stimulated with 500 µM PAR-2 AP,
two peaks of elevation of [Ca2+]in were found (Fig. 4A) ;
the first high, sharp peak (peak I) promptly appeared
and rapidly declined within 5 min, and the second
low peak (peak II) appeared gradually following
the first peak within 5-10 min after the addition of
PAR-2 AP, and was sustained during the incubation
period of 40 min. When HBEC were stimulated
with 100 µM PAR-2 AP, peak I was not detectable
while peak II was detectable (Fig. 4B).
In most of the experiments, this PAR-2 AP-induced
biphasic increase of [Ca2+]in shown in Fig. 4A was
detectable when HBEC were stimulated with 200
µM or over 200 µM of PAR-2 AP. The amplitude of
peak I increased in a dose-dependent manner in
the range of 200-500 µM of PAR-2 AP. Most previ-
ous investigators observed the rapid, sharp [Ca2+]in
increase corresponding to peak I when they simu-
lated various kinds of cells with PAR agonist serine
proteases or PAR agonist peptides, and considered
that this peak is induced via a G-protein-mediated
mechanism. These results indicate that our HBEC
have functional PAR-2.
In most of the experiments, when HBEC were
stimulated with 10-150 µM of PAR-2 AP, peak I was
not detectable, while peak II was continuously de-
tectable.
However, the minimum concentration of PAR-2
AP to induce the peak I differed in range of 100-
200 µM depending on the HBEC used.
When HBEC were stimulated with 200-500 µM
PAR-2 AP in Ca2+-free Hepes buffer, peak I appeared
but peak II did not (data not shown).
Effect of HAT on [Ca2+]in in HBEC
In the present microfluorometry assay system
of [Ca2+]in, no prominent detachment of HBEC was
observed within an incubation period of 60 min even
when HAT was added at 1,000 mU/ml (approximately
0.4 µM). Therefore, the effect of HAT on [Ca2+]in was
tested at a concentration of 1,000 mU/ml or below.
At first, the effect of HAT was examined in Hepes
buffer (pH 7.4) containing 1 mM Ca2+. When HBEC
were stimulated with 600 mU/ml of HAT, two peaks
of elevation of [Ca2+]in were found ( Fig. 5A) ; the
first high, sharp peak (peak I) appeared and rap-
idly declined within 5-10 min, and the second low
peak (peak II) appeared gradually following the first
peak within 5-15 min after the addition of HAT, and
was sustained during the incubation period of 40
min. The duration of HAT-induced peak I was rath-
er longer than that of PAR-2 AP-induced peak I
On the other hand, when HBEC were stimulated
with 60 mU/ml of HAT, peak I was not detectable
while peak II was detectable (Fig. 5C).
The HAT-induced biphasic increase of [Ca2+]in
Fig. 4. Effect of human PAR-2 agonist peptide (AP) on the
intracellular free Ca2+ concentration, [Ca2+]in in the HBEC.
After the HBEC had been proliferated on 13×13 mm cover slips
in a 6-well plate to 70% confluence in LHC9/RPMI-1640, they
were cultured in RPMI/0.01%BSA for 1 day. Then, they were
loaded with 2 µM fura-2/AM for 1 hr in 10 mM Hepes buffer
containing 145 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mMMgCl2,
5 mM glucose (pH 7.4), and stimulated at 37℃ with rHAT for
40 min. The [Ca2+]in in the HBEC was evaluated by microfluorometry
at an exitation wavelength of 340 nm and 380 nm, and at an
emission wavelength of 510 nm, and was expressed as the ratio
of fluorointensity at 340 nm to that at 380 nm. (a) 500 µM PAR-2,
(b) 100 µM PAR-2. Traces represent results in single cells from
3 experiments.
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shown in Fig. 5A was detectable when HBEC were
stimulated with a rather higher concentration of
HAT. The minimum concentration to induce peak
I differed in the range of 200-300 mU/ml (0.08-
0.12 µM) depending on the HBEC used. The am-
plitude of peak I increased in a dose-dependent
manner in the HAT concentration range of 300-
1,000 mU/ml (data not shown).
In the presence of 1-200 mU/ml of HAT, peak I
was not detectable, while peak II was continuously
detectable.
Next, the effect of HAT was examined in Ca2+-free
Hepes buffer. When HBEC were stimulated with
600 mU/ml, peak I appeared but peak II did not
(Fig. 5 B). The amplitude of peak I was rather low-
er in Ca2+-free conditions than in the Ca2+-positive
conditions. When HBEC were stimulated with 60
mU/ml of HAT, no prominent increase of [Ca2+]in
was detectable (Fig. 5D).
Both the HAT-induced peak I and II were almost
completely abolished by heating HAT at 95℃ for 5
min.
Desensitization of the Ca2+ response to HAT by
PAR-2 AP
At first, desensitization experiments were carried
out in Hepes buffer containing Ca2+.
HBEC were exposed to 500 µM PAR-2 AP. Then,
they were successively exposed to 500 µM PAR-2
and finally to 1 µM bradykinin at 5 min intervals,
without an intervening wash. As shown in Fig. 6A,
the HBEC showed a lower response to the second
PAR-2 AP than to the first PAR-2 AP, while they respond-
ed well to a subsequent treatment with bradykinin.
Thus, the first PAR-2 AP treatment induced desen-
sitization of the calcium response to the second
PAR-2 AP treatment.
After HBEC were exposed to 500 mU/ml HAT,
they were successively exposed to 500 mU/ml HAT
and finally to 1 µM bradykinin at 5 min intervals.
The HBEC showed a lower response to the second
HAT than to the first HAT treatment, while they
responded well to a subsequent treatment with
bradykinin, as shown in Fig. 6 B.
After HBEC were exposed to 500 µM PAR-2 AP,
they were successively exposed to 500 mU/ml HAT
and 1 µM bradykinin at 5 min intervals. As shown
in Fig. 6C, PAR-2 AP induced desensitization of the
calcium response to HAT ; most of the cells showed
no significant Ca2+ response to HAT. Nevertheless,
they responded well to a subsequent treatment with
1 µM bradykinin.
The same experiment was carried out in Ca2+-free
Hepes buffer (data not shown). In this condition,
HAT (500 mU/ml) markedly decreased the calcium
response to PAR-2 AP (500 µM). PAR-2 AP (500 µM)
Fig. 5. Effect of rHAT on the [Ca2+]in in the HBEC.
Unless otherwise stated, the experimental procedures were essentially the same as those for Fig. 4. When the effect of rHAT on the
[Ca2+]in in the HBEC was tested in a Ca2+-free condition, a 10 mM Hepes buffer which contained 1 mM EGTA instead of 1 mM CaCl2
was used instead of the Hepes buffer. (A) stimulated with 600 mU/ml rHAT in the presence of extracellular Ca2+, (B) stimulated
with 600 mU/ml rHAT in the absence of extracellular Ca2+, (C) stimulated with 60 mU/ml rHAT in the presence of extracellular
Ca2+, (D) stimulated with 60 mU/ml rHAT in the absence of extracellular Ca2+. Traces represent results in single cells from 3 experi-
ments.
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markedly decreased the calcium response to HAT
(500 mU/ml) as in the experiment using Hepes
buffer containing Ca2+.
Characterization of Ca2+ response to HAT in HBEC
To characterize the mechanism of increase of
[Ca2+]in in HBEC by HAT, we examined the effects
of pertussis toxin, a G-protein-coupled receptor in-
hibitor, and U73122, a phospholipase C inhibitor,
on the HAT-induced [Ca2+]in increases in HBEC.
The HBEC were pre-incubated with 50 µM pertussis
toxin for 2 hrs, and then incubated with 600 mU/
ml HAT and 50 µM pertussis toxin. The pretreatment
of HBEC with pertussis toxin had no significant ef-
fect on both 600 mU/ml HAT-induced peak I and
peak II (Fig. 7B).
The HBEC were pre-incubated with 4 µM U73122,
and then incubated with 600 mU/ml HAT and 4 µM
U73122. The U73122 treatment almost completely
abolished peak I, but had no significant effect on
peak II (Fig. 7C).
DISCUSSION
In this study, the expression of HAT mRNA was
detectable only in primary bronchial epithelial cells
such as HBEC and SAEC, but not in BEAS-2B, a
transformed bronchial epithelial cell, as well as in
alveolar macrophages, lung fibroblasts and an al-
veolar cell line (A549). This result supported the
immunohistochemical findings by Takahashi et al.
(10) showing that HAT is synthesized in the airway
Fig. 6. Desensitization of the Ca2+ response to HAT by PAR-2
AP.
HBEC were exposed to the first agonist in the Hepes buffer
containing Ca2+. Then they were successively exposed to the
second agonist and finally to 1 µM bradykinin at 5 min inter-
vals, without an intervening wash. (A) HBEC were subjected to
two consecutive 500 µM PAR-2 AP exposures, and finally exposed
to 1 µM bradykinin, (B) HBEC were subjected to two consecu-
tive exposures to 500 mU/ml HAT, and finally exposed to 1
µM bradykinin, (C) HBEC were successively exposed to 500
µM PAR-2 AP, 500 mU/ml HAT, and 1 µM bradykinin. Traces
represent results in single cells.
Fig. 7. Effects of pertussis toxin and U73122 on the rHAT-induced
[Ca2+]in increase in the HBEC
(A) HBEC were stimulated with 600 mU/ml HAT. (B) HBEC
were pre-incubated with 50 µM pertussis toxin for 2 hrs, and
then incubated with 600 mU/ml HAT and 50 µM pertussis tox-
in. (C) HBEC were pre-incubated with 4 µM U73122 for 30
min, and then incubated with 600 mU/ml HAT and 4 µM
U73122.
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(ciliated) epithelial cells. No expression of HAT mRNA
in the BEAS-2B is considered to be due to the fact
that transformed bronchial epithelial cells lose vari-
ous kinds of native properties of bronchial epithe-
lial cells during transformation and repeated culture.
RT-PCR analysis of the expression of mRNA of
PAR-1, 2, 3 and 4 in the HBEC showed that HBEC
contains much more PAR-2 mRNA than mRNA of
other known PARs. Ubl et al. showed the expression
of PAR-2 mRNA in HBEC using RT-PCR (39) and
the expression of PAR-2 in bronchial epithelial cells
was immunohistochemically shown by previous
studies (5-6). The biochemical structure of HAT
differs from that of mast cell tryptase (MCT), and
the substrate specificity against fluorogenic syn-
thetic substrates of HAT was different from that of
MCT (3, 38). However, HAT and MCT showed simi-
lar substrate specificities against native proteins.
HAT showed limited proteolysis against fibrinogen
(3, 39), single-chain urinary-type plasminogen acti-
vator (40) and vasoactive peptide (unpublished), in
the same way as MCT (41-43). On the other hand,
PAR-2 is activated not only by trypsin (16-17) but
also by MCT (12, 22, 23). These results strongly
suggested that HAT can activate PAR-2 at the airway
epithelium.
The PAR-2 agonist peptide (PAR-2 AP) corres-
ponds to a new NH2-terminus which is produced
when PAR-2 is activated by limited proteolysis of
its extracellular NH2-terminus with trypsin, and acts
as a tethered ligand (20). The present study showed
that human PAR-2 AP over 150-200 µM induced a
prompt increase of [Ca2+]in, which occurred within
2-5 min, indicating that our HBEC contain a func-
tional PAR-2. We named this prompt increase of
[Ca2+]in as peak I.
HAT over 200-300 mU/ml also induced a prompt
increase of [Ca2+]in in HBEC. The time course of
HAT-induced peak I was very similar to that of PAR-2
AP-induced peak I, although the duration of the
former was slightly longer than that of the latter.
Both HAT-induced peak I and PAR-2 AP-induced
peak I are thought to be caused by Ca2+ mobiliza-
tion from intracellular stores, because they appeared
even when HBEC were incubated in Ca2+-free Hepes
buffer.
The present study showed that both PAR-2 AP
and HAT induced a second low [Ca2+]in peak (peak
II), which appeard gradually following peak I. Peak
II was induced not only by a high dose of HAT (over
200-300 mU/ml) and a high dose PAR-2 AP (over
150-200 µM), but also by a low dose of HAT (1-200
mU/ml) and a low dose PAR-2 AP (10-150 µM). Both
PAR-2 AP-induced and HAT-induced peak II were
abolished when the HBEC were incubated in Ca2+-free
Hepes buffer. These results strongly suggested that
peak II is induced by an influx of extracellular Ca2+.
Previously, Bohm et al. (36) reported that tryp-
sin induced biphasic [Ca2+]in elevations in both in-
testinal epithelial cells and in kidney epithelial cells
transfected with cDNA encoding human PAR-2 ;
trypsin stimulated a prompt increase in [Ca2+]in due
to the mobilization of intracellular Ca2+, followed by
a sustained plateau due to the influx of extracellular
Ca2+. The former increase and the latter sustained
plateau correspond to peak I and peak II in our HBEC,
respectively.
Our result showing that the increase of intracellular
Ca2+ concentration induced by HAT is very similar
to that induced by PAR-2 AP in HBEC strongly
suggested that HAT may induce the increase of
intracellular Ca2+ concentration in these cells via the
activation of PAR-2. Furthermore, this effect of HAT
is thought to be due to its enzymatic action, be-
cause it was abolished by heat treatment of HAT.
The desensitization of the Ca2+ response to PAR-2
agonist protease (trypsin) or PAR-2 AP with these
agonists in the cells which contain PAR-2 was shown
by previous investigators ; Bohm et al. showed that
exposure of the intestinal and kidney epithelial cells
to the PAR-2 AP or trypsin results in desensitization
of the Ca2+ response in these cells (36). Trypsin and
PAR-2 AP increased the levels of intracellular cal-
cium in human airway smooth muscle cells, with
evident desensitization after treatment with either
agonist (12).
In the present study, exposure of the HBEC to
500 µM PAR-2 AP before 500 µM PAR-2 AP or 500
mU/ml HAT treatment almost completely abolished
the Ca2+ response to the latter agonist treatment, and
exposure of the HBEC to 500 mU/ml HAT marked-
ly decreased the Ca2+ response to the second HAT
treatment. In all experiments, the Ca2+ response to
bradykinin was constantly detectable. These results
indicate that both HAT and PAR-2 AP increase
intracellular calcium by acting via the PAR-2 recep-
tor, while bradykinin increases intracellular calcium
via a different receptor mechanism, supporting the
idea that HAT induces the elevation of [Ca2+]in in
HBEC via the activation of PAR-2.
The HAT-induced peak I was not inhibited by 50
µM pertussis toxin but was inhibited by 4 µM U73122,
a phospholipase C inhibitor. These results indicated
that HAT may trigger Ca2+ release from intracellular
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Ca2+ stores (peak I), probably via the activation of
PAR-2 followed by a pertussis toxin-insensitive
G-protein-mediated activation of phospholipase C.
On the other hand, the HAT-induced peak II was
not inhibited by 50 µM pertussis toxin and 4 µM
U73122. These results strongly suggested that peak
II is induced by an influx of extracellular Ca2+ in a
mechanism related to the activation of PAR-2, but
different from the pathway which induces peak I,
and that HAT and the activation of PAR-2 induce
the [Ca2+]in elevation at least via two different mecha-
nisms in the airway epithelial cells. The intracellular
free calcium ion is related to transmission of sig-
nals from extracellular stimuli to various kinds of
cellular functions. The difference in the physiologi-
cal significance of peak I and II is unknown.
Finally, the results of the present study indicate
that HAT may activate PAR-2 in human airway epi-
thelial cells. Recent reports showed that PAR-2 is
related to the regulation of various kinds of cellular
functions, such as prostaglandin synthesis (5-6), ion
transport (29) and cytokine production (37) of air-
way epithelial cells. We also obtained a result show-
ing that HAT enhances cytokine production in HBEC
via activation of PAR-2 (unpublished). These results
strongly suggest that HAT may be related to regu-
lation of cellular functions of airway epithelial cells
via activation of PAR-2.
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